Skip to content

Study · Randomized controlled trial · n = 136 · 2012

1 result

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol.

Rabati BK, Zeidi SN

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences1 Nov 2012Cited by 10 (Europe PMC)

PMID23833582 (opens in a new tab)PMCIDPMC3702089 (opens in a new tab)PepBankPUB-23833582
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In ART candidates, cetrorelix and buserelin protocols did not differ significantly in ovarian stimulation, pregnancy outcomes or OHSS rates.

    In plain wordsIn ART candidates, cetrorelix and buserelin protocols did not differ significantly in ovarian stimulation, pregnancy outcomes or OHSS rates.

    Peptide
    Cetrorelix
    Outcome
    No significant changeOvarian stimulation, pregnancy outcomes and OHSS
    Study

    n = 136

    Comparator
    Buserelin protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were not significant differences between 2 groups regarding the ovarian stimulation, pregnancy outcomes and rate of OHSS (P value >0.05).
    2 context sentences
    Summary · context
    This investigation was performed on 136 patients who were randomly allocated to two groups of GnRH agonist and GnRH antagonist.
    Summary · context
    In the first group stimulation was performed by administration of Buserelin, and in the second group, it was performed by giving Cetrorelix.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.